Cereblon (CRBN), originally identified as a gene associated with intellectual disability, was
identified as primary target of thalidomide. Accumulating evidence has shown that CRBN is …

Thalidomide, well known for its potent teratogenicity, has been re-evaluated as a clinically
effective drug for the treatment of multiple myeloma. Although the direct target of thalidomide …

Cereblon (CRBN) is a substrate recognition protein in the E3-ligase ubiquitin complex. The
binding target of CRBN varies according to tissues and cells, and the protein regulates …

Targeted protein degradation has become an exciting new paradigm in drug discovery with
the potential to target new protein families for therapeutic intervention. In 2010, Hiroshi …

Targeted protein degradation via cereblon (CRBN), a substrate receptor of an E3 ubiquitin
ligase complex, is an increasingly important strategy in various clinical settings, in which the …

Progress in strategies aimed at breaking down therapeutic target proteins has led to a
paradigm shift in drug discovery. Thalidomide and its derivatives are the only protein …

Cereblon serves as an ubiquitin ligase substrate receptor that can be tuned toward different
target proteins by various cereblon-binding agents. This offers one of the most promising …

Introduction Cereblon (CRBN), the substrate receptor of the CRL4CRBN E3 ubiquitin ligase
has been extensively studied due to its involvement in many biological processes. It has …

Upon binding to thalidomide and other immunomodulatory drugs, the E3 ligase substrate
receptor cereblon (CRBN) promotes proteosomal destruction by engaging the DDB1 …

Cereblon (CRBN) is a ubiquitin ligase (E3) substrate receptor protein co-opted by CRBN E3
ligase modulatory drug (CELMoD) agents that target therapeutically relevant proteins for …